LENZ Therapeutics (LENZ) Cash from Operations Growth (1y) (2021 - 2026)

LENZ Therapeutics (LENZ) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (1y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 7.14%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 356.73%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 74.39%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 3.23%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 LENZ Therapeutics 158.34 Mn 158.34 Mn 825,000.00 -109.25%

Historic Data

Download Data
DateValue
Mar 31, 2026 -109.25%
Dec 31, 2025 -263.79%
Sep 30, 2025 18.84%
Jun 30, 2025 27.14%
Mar 31, 2025 32.95%
Dec 31, 2024 56.71%
Sep 30, 2024 19.15%
Jun 30, 2024 -16.79%
Mar 31, 2024 -87.04%
Dec 31, 2023 6.50%
Sep 30, 2023 41.09%
Jun 30, 2023 38.79%
Mar 31, 2023 39.75%
Dec 31, 2022 -43.84%
Sep 30, 2022 -44.13%
Jun 30, 2022 -60.29%
Mar 31, 2022 -163.52%
Dec 31, 2021 -195.83%
Sep 30, 2021 -518.33%